ECOG-ACRIN EA9171

Primary Category:

Treatment Protocols

Disease Category:

Chronic Myeloid Leukemia, Leukemia

Status:

New, Open

Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

NCT#03516279